The study explored the activation of
G-proteins by the
5-HT1F receptor agonist
LY334370 in guinea-pig brain sections and cell lines expressing human
5-HT1A receptors. Autoradiography and [35S]-GTPγS binding responses were used to assess the agonist's activity.
In guinea-pig brain regions known for 5-HT1F binding sites, LY334370 did not stimulate [35S]-GTPγS binding. However, when applied to brain sections, it increased [35S]-GTPγS binding in areas such as the hippocampus, lateral septum, dorsal raphe, entorhinal, and cingulate cortex—regions associated with 5-HT1A receptor-mediated G-protein activation. The agonist's effect was blocked by the selective 5-HT1A receptor antagonist
WAY100635, suggesting that LY334370-induced response in guinea-pig brain is indeed mediated by 5-HT1A receptors.
The maximal [35S]-GTPγS binding response induced by LY334370 in recombinant C6-glial/h 5-HT1A and HeLa/h 5-HT1A cells was similar to that of 5-HT, indicating high intrinsic activity of LY334370 at h 5-HT1A receptors.
The findings conclude that LY334370 induces G-protein activation in guinea-pig brain sections and recombinant cell lines through 5-HT1A receptors, not 5-HT1F as initially presumed. This indicates that caution should be exercised when using LY334370 as a selective 5-HT1F agonist.
How to Use Synapse Database to Search and Analyze Translational Medicine Data?
The transational medicine section of the Synapse database supports searches based on fields such as drug, target, and indication, covering the T0-T3 stages of translation. Additionally, it offers a historical conference search function as well as filtering options, view modes, translation services, and highlights summaries, providing you with a unique search experience.

Taking obesity as an example, select "obesity" under the indication category and click search to enter the Translational Medicine results list page. By clicking on the title, you can directly navigate to the original page.

By clicking the analysis button, you can observe that GLP-1R treatment for obesity has gained significant attention over the past three years, with preclinical research still ongoing in 2023. Additionally, there are emerging potential targets, such as GDF15, among others.

Click on the image below to go directly to the Translational Medicine search interface.
